Diagnostic, Prognostic, and Therapeutic Biomarkers for Ovarian Cancer

Dear Colleagues,

Despite the development of several treatment options, ovarian cancer remains a major cause of death for women worldwide. Early diagnosis is one of the most important factors that determine survival from ovarian cancer. However, current clinical diagnostic tools have limited efficacy for the early detection of this cancer type, hence there is an urgent need for new diagnostic biomarkers. Advances in knowledge acquired from genomic, metabolomic and proteomic techniques should lead to the discovery of novel biomarkers with clinical utility for the diagnosis, prognostic assessment, and therapeutic evaluation of ovarian cancer. Specific diagnostic biomarkers may therefore have profound diagnostic, prognostic and therapeutic implications for ovarian cancer.

Dr.  Juan Zhou

Guest Editor

Manuscripts should be submitted via our online editorial system at https://imr.propub.com by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 2500 USD. Submitted manuscripts should be well formatted in good English.